John Evans, Beam Therapeutics CEO
Beam's base-edited allogeneic CAR-T gets FDA go-ahead after four-month wait
The FDA wanted more information on four key areas before it would let Beam Therapeutics proceed with human testing for a cell therapy in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
